Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | RXRG | P48443 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6603683 | 0.89 | ALDH1A1 (0.39) | RXRARXRBRXRGMEN1MAPT | |
| SCHEMBL7508759 | 0.89 | RXRA (0.49) | RXRARXRBRXRGPTGS1EPHX2 | |
| SCHEMBL1362566 | 0.83 | PTGS1 (0.36) | RXRARXRBRXRGPTGS1EPHX2 | |
| SCHEMBL1361608 | 0.83 | PTPN1 (0.38) | MEN1MAPTKMT2ACYP3A4CYP2D6 | |
| SCHEMBL5206674 | 0.81 | MKNK1 (0.46) | RXRARXRBRXRGMEN1MAPT | |
| SCHEMBL1362051 | 0.79 | MEN1 (0.46) | RXRARXRBRXRGMEN1MAPT | |
| SCHEMBL6606347 | 0.78 | RXRA (0.47) | RXRARXRBRXRGMAPTHPGD | |
| SCHEMBL5210693 | 0.78 | ALDH1A1 (0.40) | RXRARXRBRXRGMEN1MAPT | |
| SCHEMBL1362046 | 0.78 | PPARD (0.36) | MEN1MAPTKMT2ACYP3A4PPARD | |
| SCHEMBL1361008 | 0.78 | PTGS1 (0.34) | RXRARXRBRXRGMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067453-B2 | Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-7396848-B1 | oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| US-6699995-B1 | ALKYLATION AT 5-POSITION OF OXAZOLE BY REACTION WITH UNSATURATED COMPOUND IN PRESENCE OF ACID OR BASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-03-02 | — | — | US | disclosed |
| EP-1219610-B1 | PROCESS FOR THE PREPARATION OF OXAZOLE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6605629-B1 | Oxazole derivatives; low toxicity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| EP-1219610-A1 | PROCESS FOR THE PREPARATION OF OXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | BDNF, NGF, NTRK2 | RXRA 1722/4885RXRB 1478/4885RXRG 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.